The Potential Havoc Of Generic Drug Tariffs

In this week’s edition of InnovationRx, we look at the havoc of generic drug tariffs, the companies looking to cash in on the coming peptide bonanza, the ongoing cyclosporiasis outbreak, Tempus’s acquisition of a cancer-testing company, and more. To get it in your inbox, subscribe here.